ThromboGenics drug pipeline on track

* Cash shrinks due to cost of late-stage trials

* 9-month revenue 3.7 mln euros vs 30.3 mln 9-months 2008

* Shares up 2.3 percent

BRUSSELS, Nov 4 (Reuters) - Belgian biotech company ThromboGenics NV (THR.BR: Quote, Profile, Research) is on track with its drug development pipeline and its partnership with Swiss drugmaker Roche AG (ROG.VX: Quote, Profile, Research) is making good progress, it said on Wednesday.

Thrombogenics, which develops drugs for conditions related to the vascular system, such as cardiovascular disease, visual disorders and cancer, said it had completed patient enrolment for the U.S. Phase III study of its lead product microplasmin for treatment of back-of-the-eye disease.

Recruitment for its second Phase III trial was making good progress, it said.

It had also completed patient recruitment for a Phase II study for TB-402, its drug to prevent blood clots developed in conjunction with Sweden's BioInvent (BINV.ST: Quote, Profile, Research).

The group's partnership with Roche for the development of anti-cancer drug TB-403 was also on track, it said.